These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 11177653)

  • 1. Coronary artery reactivity after treatment with simvastatin.
    Vita JA; Yeung AC; Winniford M
    Curr Atheroscler Rep; 2001 Mar; 3(2):105-8. PubMed ID: 11177653
    [No Abstract]   [Full Text] [Related]  

  • 2. Post hoc analysis of coronary findings from the prospective randomized evaluation of the vascular effects of the Norvasc trial (PREVENT).
    Mancini GB; Miller ME; Evans GW; Byington R; Furberg CD; Pitt B;
    Am J Cardiol; 2002 Jun; 89(12):1414-6. PubMed ID: 12062738
    [No Abstract]   [Full Text] [Related]  

  • 3. Coronary artery disease: the Scandinavian Simvastatin Survival Study experience.
    Pedersen TR
    Am J Cardiol; 1998 Nov; 82(10B):53T-56T. PubMed ID: 9860376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coronary angiographic changes in patients with cardiac events in the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT).
    Mancini GB; Pitt B
    Am J Cardiol; 2002 Oct; 90(7):776-8. PubMed ID: 12356398
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of the metabolic syndrome and hyperuricemia on outcome in patients with coronary artery disease (from the Bezafibrate Infarction Prevention Study).
    Brodov Y; Behar S; Boyko V; Chouraqui P
    Am J Cardiol; 2010 Dec; 106(12):1717-20. PubMed ID: 21126615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do ACE inhibitors have a real role in coronary artery disease?
    Cardiovasc J S Afr; 2003; 14(3):156. PubMed ID: 12934579
    [No Abstract]   [Full Text] [Related]  

  • 7. Serum insulin-like growth factor-I level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: beneficial effects of bezafibrate treatment.
    Ruotolo G; Båvenholm P; Brismar K; Eféndic S; Ericsson CG; de Faire U; Nilsson J; Hamsten A
    J Am Coll Cardiol; 2000 Mar; 35(3):647-54. PubMed ID: 10716467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of stroke and myocardial infarction by amlodipine and Angiotensin receptor blockers: a quantitative overview.
    Wang JG; Li Y; Franklin SS; Safar M
    Hypertension; 2007 Jul; 50(1):181-8. PubMed ID: 17502490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antihypertensive therapy: campaign of the giants].
    Füessl HS
    MMW Fortschr Med; 2005 Dec; 147(51-52):28. PubMed ID: 16402700
    [No Abstract]   [Full Text] [Related]  

  • 10. Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).
    de Faire U; Ericsson CG; Grip L; Nilsson J; Svane B; Hamsten A
    Eur Heart J; 1996 Dec; 17 Suppl F():37-42. PubMed ID: 8960446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of aggressive statin therapy on patients with coronary saphenous vein bypass grafts: a systematic review and meta-analysis of randomized, controlled trials.
    Kang S; Liu Y; Liu XB
    Clin Ther; 2013 Aug; 35(8):1125-36. PubMed ID: 23932462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the Coronary AngioPlasty Amlodipine REStenosis Study (CAPARES).
    Jørgensen B; Simonsen S; Endresen K; Forfang K; Vatne K; Hansen J; Webb J; Buller C; Goulet G; Erikssen J; Thaulow E
    J Am Coll Cardiol; 2000 Mar; 35(3):592-9. PubMed ID: 10716459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New pathophysiological insights explain life-saving benefits of perindopril in coronary artery disease patients.
    Cardiovasc J S Afr; 2004; 15(5):248-9. PubMed ID: 15483736
    [No Abstract]   [Full Text] [Related]  

  • 14. MRC/BHF Heart Protection Study.
    Wald N; Law M;
    Lancet; 2002 Nov; 360(9347):1781; author reply 1783-4. PubMed ID: 12480448
    [No Abstract]   [Full Text] [Related]  

  • 15. Rationale, design, and baseline characteristics of the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT).
    Byington RP; Miller ME; Herrington D; Riley W; Pitt B; Furberg CD; Hunninghake DB; Mancini GB
    Am J Cardiol; 1997 Oct; 80(8):1087-90. PubMed ID: 9352986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).
    Ruotolo G; Ericsson CG; Tettamanti C; Karpe F; Grip L; Svane B; Nilsson J; de Faire U; Hamsten A
    J Am Coll Cardiol; 1998 Nov; 32(6):1648-56. PubMed ID: 9822092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statins and secondary prevention of coronary heart disease.
    Ahmed M; Griffiths P
    Br J Community Nurs; 2004 Apr; 9(4):160-5. PubMed ID: 15150487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: One year perspective on COURAGE.
    Sedlis SP; Boden WE; Weintraub WS; Maron DS; O'Rourke RA; Berman DS; Mancini GB;
    Catheter Cardiovasc Interv; 2009 Feb; 73(3):428. PubMed ID: 19133682
    [No Abstract]   [Full Text] [Related]  

  • 19. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
    Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
    Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is FAME 2 a breakthrough for PCI in stable coronary disease?
    Sechtem U
    Clin Res Cardiol; 2015 Apr; 104(4):283-7. PubMed ID: 25479819
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.